Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 15/20 | 0.40 |
| ▸ | MMP1 | P03956 | 4/20 | 0.40 |
| ▸ | MMP9 | P14780 | 4/20 | 0.40 |
| ▸ | MMP13 | P45452 | 4/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP7 | P09237 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | CTRC | Q99895 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6929248 | 0.87 | F2 (0.46) | F2F10PRSS2CTRC | |
| SCHEMBL6750001 | 0.87 | F2 (0.46) | F2F10PRSS2CTRC | |
| SCHEMBL6746026 | 0.85 | F2 (0.49) | F2F10PRSS2CTRC | |
| SCHEMBL6749117 | 0.82 | F2 (0.44) | F2F10PRSS2CTRC | |
| SCHEMBL6852888 | 0.81 | F2 (0.47) | F2F10PRSS2CTRC | |
| Hydrochloric Acid SCHEMBL6745810 | 0.81 | F2 (0.46) | F2F10PRSS2CTRC | |
| SCHEMBL6745617 | 0.77 | MMP1 (0.43) | MMP1MMP9MMP13MMP3MMP7 | |
| SCHEMBL6745848 | 0.74 | MMP1 (0.43) | MMP1MMP9MMP13MMP3MMP7 | |
| SCHEMBL6750484 | 0.72 | F2 (0.36) | F2F10PRSS2CTRC | |
| SCHEMBL6749672 | 0.72 | NPC1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6518310-B2 | Non-peptidic; inhibits trypsin-like protease, thrombin and embolus formation; anticoagulant | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-02-11 | — | — | US | disclosed |
| US-20010037039-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037039-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | F9, PLG, MMP9 | F2 32/4885MMP1 21/4885MMP9 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.